



revista portuguesa de
PNEUMOLOGIA
portuguese journal of pulmonology

www.revportpneumol.org



EDITORIAL

More Global More Portugal



This will be the last edition under the name of Revista Portuguesa de Pneumologia/Pulmonology Portuguese Journal. Since 1995, the Sociedade Portuguesa de Pneumologia official journal was published under that name, following some years under its initial name of Arquivos da Sociedade Portuguesa de Patologia Respiratória. Along these years we have witnessed an outstanding evolution, that is to say the Medline indexation in 2003 and the progressive increase in the impact factor since 2011, the first year that this metric classification was attributed by Thomson Reuters^{1–5}. This positive journey has only been possible because of a significant increase in the quality of the papers, in their scientific content combined with a demanding editorial policy. The new name PULMONOLOGY, as has previously been explained, is the final stage of this evolution and its main objective is to facilitate the international visibility of the journal in the very demanding arena of respiratory journals³. Our main slogan could be 'more Global more Portugal'. However, it is only a step forward, one that was planned some years ago^{6,7}. For those who are afraid that the nature of the journal is changing, I want to reassure them that we are undertaking this in the profound belief that this is the journal of Portuguese Respiratory Society. We strongly believe that this is the right way to assist and preserve Portuguese respiratory research and publication, since the main editorial team will continue to be national, but their visibility and recognition will increase in an international journal open to international authors, reviewers and associate editors. What we are doing now can somehow be compared to a family deciding to repaint the outside of their home to make it more fashionable and attractive.

The publications in recent years on a diverse number of topics have maintained PJP as a general respiratory journal, since these have covered a wide diversity of respiratory topics^{8–17}. The most popular issues, the consequence of the respiratory disorders with the highest social impact and also the object of interest and research of a higher number of investigators, have been predominant. The highest number of original manuscripts was on the subject of obstructive disorders such as COPD or asthma and sleeping breathing disorders with all their related topics^{8–13}. However, we have had the opportunity to publish articles related with other topics, like lung cancer, bronchiectasis, cystic fibrosis,

tuberculosis and even papers with an interface with other specializations such as Pediatrics or Epidemiology, and we think that this is the right direction for a journal which is open to the whole variety of respiratory research and which is also a forum for scientific discussion not only with other respiratory physicians but also with those who in their work are in some way connected with the respiratory system^{14–18}. We have also noted an increase in the number of consensus documents and guidelines resulting from panel discussions that have included the national experts from the main respiratory pathologies^{19–22}. Publication of national and regional studies focused on patients with rare diseases will certainly increase our awareness of the main characteristics of these diseases and how the diagnostic approach is achieved^{14,15,23}. We have persisted in our policy of inviting international reference authors to write an editorial when we considered that some manuscript could provoke discussion and/or promotion of a hot topic or a new idea^{24–26}.

Another significant change in the structure of the journal has been the progressive increase in number and impact of the Letters to Editor. Our editorial policy clearly stimulates this type of publication,²⁷ which only became a regular feature in all editions in 2014. After that, in 2016 the letters to editor in a regular number of eight per edition were divided into research letters including those which contain research data, letters to editor related with clinical cases or considerations about a relevant topic related with respiratory diseases and finally in correspondence letters related with comments regarding data published previously in the journal. We have seen with particular pleasure the increasing predominance of research letters^{28–30}.

This is the editorial policy that will be adopted from the beginning of PULMONOLOGY and we are certain that this new phase of our journal will have the commitment of all the members of our society, something which is absolutely essential for our future success.

References

1. Morais A. Impact factor 0.562 - the ultimate goal or the next step forward? *Rev Port Pneumol.* 2013;19:189.
2. Morais A. Impact factor 0.85 - the ultimate goal or the next step forward? (II). *Rev Port Pneumol.* 2014;20:233–4.

<https://doi.org/10.1016/j.rppnen.2017.11.005>

2173-5115/© 2017 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

3. Morais A. Impact factor 1.16 - the big challenge and the great opportunity. *Rev Port Pneumol.* 2015;21:225–6.
4. Morais A. Impact Factor 1.35 Once again; what should and could we do about it? *Rev Port Pneumol.* 2016;22:305–7.
5. Morais A. Are we ready to get in the eye of the storm? *Rev Port Pneumol.* 2017;23:243–4.
6. Winck JC, Morais A. Shaping the future of the Portuguese Journal of Pulmonology. *Rev Port Pneumol.* 2011;17:1–2.
7. Winck JC, Morais A. Welcome to the electronic revolution. *Rev Port Pneumol.* 2011;17:49–50.
8. Couto M, Silva D, Santos P, Queirós S, Delgado L, Moreira A. Exploratory study comparing dysautonomia between asthmatic and non-asthmatic elite swimmers. *Rev Port Pneumol.* 2015;21:22–9.
9. Resende EP, Todo-Bom A, Loureiro C, Mota Pinto A, Oliveiros B, Mesquita L, Silva HC. Asthma and rhinitis have different genetic profiles for *IL13*, *IL17A* and *GSTP1* polymorphisms. *Rev Port Pneumol.* 2017;23:10–6.
10. Da Silva GPF, Pessoa Morano MTA, De Matos Cavalcante AG, De Andrade NM, De Francesco Daher E, Pereira EDB. Exercise capacity impairment in COPD patients with comorbidities. *Rev Port Pneumol.* 2015;21:233–8.
11. Alfonso M, Bustamante V, Cebollero P, Antón M, Herrero S, Gáldiz JB. Assessment of dyspnea and dynamic hyperinflation in male patients with chronic obstructive pulmonary disease during a six minute walk test and an incremental treadmill cardiorespiratory exercise test. *Rev Port Pneumol.* 2017;23:266–72.
12. Reis R, Teixeira F, Martins V, Sousa L, Batata L, Santos C, Moutinho J. Validation of a Portuguese version of the STOP-Bang questionnaire as a screening tool for obstructive sleep apnea: Analysis in a sleep clinic. *Rev Port Pneumol.* 2015;21:61–8.
13. Rodrigues AP, Pinto P, Nunes B, Bárbara C. Obstructive Sleep Apnea: Epidemiology and Portuguese patients profile. *Rev Port Pneumol.* 2017;23:57–61.
14. Amorim A, Bento J, Vaz AP, Gomes I, de Gracia J, Hespanhol V, Marques A. Bronchiectasis: A retrospective study of clinical and aetiological investigation in a general respiratory department. *Rev Port Pneumol.* 2015;21:5–10.
15. Silva A, Amorim A, Azevedo P, Lopes C, Gamboa F. Cystic fibrosis – characterization of the adult population in Portugal. *Rev Port Pneumol.* 2016;22:141–5.
16. Arbex MA, Bonini EH, Kawakame Pirolla G, D'Ambrosio L, Centis R, Migliori GB. Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil. *Rev Port Pneumol.* 2016;22:337–41.
17. Sousa Vítor, Bastos Bruno, Silva Maria, Alarcão Ana Maria, Carvalho Lina. Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways. *Rev Port Pneumol.* 2015;21:259–70.
18. Lamas-Pinheiro R, Henriques-Coelho T, Fernandes S, Correia F, Ferraz C, Guedes-Vaz L, Azevedo I, Estevão-Costa J. Thoracoscopy in the management of pediatric empyemas. *Rev Port Pneumol.* 2016;22:157–62.
19. Ferreira J, Drummond M, Pires N, Reis G, Alves C, Robalo-Cordeiro C. Optimal treatment sequence in COPD: Can a consensus be found? *Rev Port Pneumol.* 2016;22:39–49.
20. Robalo Cordeiro C, Campos P, Carvalho L, Campinha S, Clemente S, Figueiredo L, Jesus JM, Marques A, Souto-Moura C, Pinto Basto R, Ribeiro A, Serrado M, Morais A. Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis. *Rev Port Pneumol.* 2016;22:112–22.
21. Recommendations for aetiological diagnosis of bronchiectasis. *Rev Port Pneumol.* 2016;22:222–35.
22. Figueira L, Fonseca S, Ladeira I, Duarte R. Ocular tuberculosis: Position paper on diagnosis and treatment management. *Rev Port Pneumol.* 2017;23:31–8.
23. Cardoso AV, Mota PC, Melo N, Guimarães S, Souto Moura C, Jesus JM, Cunha R, Morais A. Analysis of sarcoidosis in the Oporto region (Portugal). *Rev Port Pneumol.* 2017;23:251–8.
24. Agustí Alvar. Inhaled steroids in COPD: Reasons for a debate. *Rev Port Pneumol.* 2015;21:175–7.
25. Chung KF. A silent revolution: phenotyping asthma for personalised medicine. *Rev Port Pneumol.* 2015;21:293–4.
26. Baughman RP, Lower EE. Measuring sarcoidosis around the world: Using the same ruler. *Rev Port Pneumol.* 2017;23:247–8.
27. Winck JC, Morais A. Letters to the Editor: Like a rolling stone? *Rev Port Pneumol.* 2012;18:1–2.
28. Mineiro MA, da Silva PM, Alves M, Virella D, Gomes MJM, Cardoso J. Impact of sleepiness on arterial stiffness and cardio-vascular risk in men with moderate to severe obstructive sleep apnea. *Rev Port Pneumol.* 2016;22:177–8.
29. Demelo-Rodríguez P, Olmedo Samperio M, Gaitán Tocora DG, Cano Ballesteros JC, del Toro Cervera J, Andueza Lillo JA. High-flow oxygen therapy through nasal cannula: Prospective observational study in an intermediate care unit. *Rev Port Pneumol.* 2016;22:292–3.
30. Ortiz S, Tortosa F. Pulmonary placental transmogrification: The last 16 years in a reference centre. *Rev Port Pneumol.* 2017;23:164–6.

António Morais
Editor-in-Chief

E-mail address: antonio.moraisrpp@gmail.com